If the final data is available in 2 weeks from the AIPAC11b trial and we have advertised for a manufacturing manager then why do we need to do a phase 3 trial and delay the commercial production? Is it purely a business joint venture with the likes of Merck that needs to be finalised? Or does the likes of EMA and FDA want even more proof after next months results.
In any case if the data in Dec2020 and Nov 2021 is good then bring on 2022 as i believe we will have a business.
Ann: Immutep receives EMA scientific advice for Phase 3 in MBC, page-8
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $559.2M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 39.0¢ | 37.0¢ | $1.152M | 3.025M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 83872 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 138206 | 18 |
View Market Depth
| Last trade - 13.34pm 28/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |